|
|||||
|
|
| 生物治疗在重症哮喘中的应用现状和前景 | |
| 引用本文： | 张艳培,黄楠,彭君,符筱,李嘉,董航明. 生物治疗在重症哮喘中的应用现状和前景[J]. 国际呼吸杂志, 2021, 41(4): 283-290 |
| 作者姓名： | 张艳培 黄楠 彭君 符筱 李嘉 董航明 |
| 作者单位： | 南方医科大学第一临床医学院，广州 510515;南方医科大学南方医院呼吸与危重症医学科，广州 510515 |
| 基金项目： | 国家自然科学基金(81870058);广东省自然科学基金(2017A030313849)。 |
| 摘 要： | 支气管哮喘(哮喘)是目前全世界最普遍的慢性病之一，80%的哮喘患者经过长期规范化治疗可达到临床控制，但仍有20%的哮喘患者表现为重症哮喘，其在第4级或第5级哮喘药物治疗下才能或甚至仍不能维持临床疗效，这给其自身和医疗系统带来巨大的负担。由于生物治疗直接针对哮喘发病的免疫机制，靶向哮喘发作的关键分子，生物治疗日益成为治疗... |
| 关 键 词： | 免疫 重症哮喘 生物治疗 |
Application status and prospect of biotherapy in severe asthma |
|
| Zhang Yanpei,Huang Nan,Peng Jun,Fu Xiao,Li Jia,Dong Hangming. Application status and prospect of biotherapy in severe asthma[J]. International Journal of Respiration, 2021, 41(4): 283-290 | |
| Authors: | Zhang Yanpei Huang Nan Peng Jun Fu Xiao Li Jia Dong Hangming |
| Affiliation: | (The First Clinical Medical College,Southern Medical University,Guangzhou 510515,China;Department of Respiratory and Critical Care Medicine,Nanfang Hospital of Southern Medical University,Guangzhou 510515,China) |
| Abstract: | Bronchial asthma(asthma)is one of the most common chronic diseases in the world.80%of patients with asthma can achieve clinical control after long-term standardized treatment,while 20%of patients still have severe asthma.Patients with severe asthma can or even cann′t maintain clinical efficacy under the treatment of grade 4 or 5 asthma drugs,which brings a huge burden to themselves and the health care system.Since biotherapy directly targets the immune mechanism of asthma and the key molecules of asthma attack,biotherapy is becoming a new star in the treatment of severe asthma.The purpose of this review is to discuss the application status and prospect of biotherapy in the severe asthma setting,and to explore the application value of biotherapy in the clinical treatment of severe asthma. |
| Keywords: | Immunity Severe asthma Biotherapy |
| 本文献已被 维普 万方数据 等数据库收录！ | |